Cargando…

Neutralizing Antibody Therapeutics for COVID-19

The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strategies. In this article, we review the role of SARS-CoV-2 neutralizing antibodies (nAbs) in the clinical management of COVID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurt, Aeron C., Wheatley, Adam K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067572/ https://www.ncbi.nlm.nih.gov/pubmed/33916927 http://dx.doi.org/10.3390/v13040628

Ejemplares similares

Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
por: Liu, Yi, et al.
Publicado: (2019)

Neutralizing monoclonal antibodies for treatment of COVID-19
por: Taylor, Peter C., et al.
Publicado: (2021)

Sequencing B cell receptors from ferrets (Mustela putorius furo)
por: Wong, Julius, et al.
Publicado: (2020)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Overview of Neutralizing Antibodies and Their Potential in COVID-19
por: Morales-Núñez, José Javier, et al.
Publicado: (2021)

Neutralizing antibodies for the prevention and treatment of COVID-19
por: Du, Lanying, et al.
Publicado: (2021)

A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade
por: Oh, Ding Yuan, et al.
Publicado: (2014)

Neutralizing antibody: a savior in the Covid-19 disease
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Antiviral Therapy for the Next Influenza Pandemic
por: Hurt, Aeron C.
Publicado: (2019)

Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective
por: Ajmeriya, Swati, et al.
Publicado: (2022)

Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
por: Jaworski, Juan Pablo
Publicado: (2021)

Influenza and COVID‐19: What does co‐existence mean?
por: Chotpitayasunondh, Tawee, et al.
Publicado: (2020)

Engineering Venom’s Toxin-Neutralizing Antibody Fragments and Its Therapeutic Potential
por: Alvarenga, Larissa M., et al.
Publicado: (2014)

Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview
por: Ali, Manasik Gumah, et al.
Publicado: (2020)

Assessment of the RNASound RNA Sampling Card for the Preservation of Influenza Virus RNA
por: Lau, Hilda, et al.
Publicado: (2016)

Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
por: Hurt, Aeron C., et al.
Publicado: (2016)

COVID-19-neutralizing antibodies predict disease severity and survival
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2021)

COVID-19 neutralizing antibodies predict disease severity and survival
por: Garcia-Beltran, Wilfredo F., et al.
Publicado: (2020)

COVID-19 reinfection in the presence of neutralizing antibodies
por: Zhang, Ju, et al.
Publicado: (2021)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Neutralizing antibody response in mild COVID-19
por: van der Heide, Verena
Publicado: (2020)

Broadly neutralizing antibodies against COVID-19
por: Zhou, Daming, et al.
Publicado: (2023)

Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness
por: Oh, Ding Y., et al.
Publicado: (2016)

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
por: Leang, Sook-Kwan, et al.
Publicado: (2017)

Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19
por: Ren, Zuning, et al.
Publicado: (2023)

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
por: Zhou, Guangyu, et al.
Publicado: (2020)

COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19
por: Yang, Lifei, et al.
Publicado: (2020)

Influenza antivirals currently in late‐phase clinical trial
por: Koszalka, Paulina, et al.
Publicado: (2017)

Letter to the editor: Neutralizing antibodies for the treatment of COVID-19
por: Zhou, Zeqi, et al.
Publicado: (2021)

COVID-19 vaccines: neutralizing antibodies and the alum advantage
por: Hotez, Peter J., et al.
Publicado: (2020)

Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
por: Suthar, Mehul S., et al.
Publicado: (2020)

Development and application of therapeutic antibodies against COVID-19
por: Ning, Lin, et al.
Publicado: (2021)

COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review
por: Focosi, Daniele, et al.
Publicado: (2021)

Delta-Omicron recombinant escapes therapeutic antibody neutralization
por: Duerr, Ralf, et al.
Publicado: (2023)

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
por: Han, Hui-Ju, et al.
Publicado: (2018)

Neutralizing Antibody Response to Hepatitis C Virus
por: Wang, Yong, et al.
Publicado: (2011)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
por: Landais, Elise, et al.
Publicado: (2018)

Author Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19
por: Lucas, Carolina, et al.
Publicado: (2021)

Current and future nanoparticle vaccines for COVID-19
por: Vu, Mai N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_js3rmlgn1p5tifgs7l5q40fc0t